COTA Team Member Spotlight: Emily Di Capua
As a company that builds solutions that analyze real-world data to deliver clinically relevant insights that improve cancer care, we want to step back and feature the wonderful COTA team members (called CO10s) who are helping us achieve this goal. This week, we’re featuring Emily Di Capua, our VP of Strategic Initiatives.
The FDA’s History with RWE – and Continued Momentum from Dr. Sharpless
Earlier this month, Dr. Scott Gottlieb, the popular FDA Commissioner, announced he is resigning. COTA’s blog explores what this means for the future of RWE and the FDA.
Reevaluating Expectations for HIT’s Biggest Bonanza
COTA’s CEO Mike Doyle highlights his key takeaways from HIMSS19 around data stockpiling, thinking like consumers, and precision medicine.
The Cancer Market is Booming – How Does That Impact Care?
It’s no secret that oncology care is at a turning point, but what does this mean for patient care? COTA’s VP of Life Sciences Viraj Narayanan explores the impact and what we can expect in the future.
Cancer Death Rate Hits 25 Years of Decline – What’s Changing?
The American Cancer Society announced promising news to start off 2019 – the overall nationwide cancer death rate has fallen continuously over the last 25 years. What changes have led to this decline?
Changing How We Treat Cancer, Beginning with Drug Approvals
Earlier this month, the FDA approved the drug Vitrakvi to treat a wide range of cancers. Andrew Norden, M.D., COTA’s Chief Medical Officer, discusses what this means for the future of cancer care and precision medicine.
CEO Corner: Mike Doyle’s First Month at COTA
New CEO Mike Doyle reflects on his first month at COTA, the impact of precision medicine in oncology, and the clinical value of real world evidence.
COTA Increases Breakthrough Capability, adds Chief Technology Officer
COTA Increases Breakthrough Capability, adds Chief Technology Officer
